BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37103683)

  • 1. Consumption of health resources in older people with differentiated thyroid carcinoma: a multicenter analysis.
    Díez JJ; Anda E; Alcazar V; Isidro ML; Familiar C; Paja M; Martín Rojas-Marcos P; Pérez-Corral B; Navarro E; Romero-Lluch AR; Oleaga A; Pamplona MJ; Fernández-García JC; Megía A; Manjón-Miguélez L; Sánchez-Ragnarsson C; Iglesias P; Sastre J
    Endocrine; 2023 Sep; 81(3):521-531. PubMed ID: 37103683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival.
    Díez JJ; Anda E; Alcazar V; Isidro ML; Familiar C; Paja M; Rojas Marcos P; Pérez-Corral B; Navarro E; Romero-Lluch AR; Oleaga A; Pamplona MJ; Fernández-García JC; Megía A; Manjón L; Sánchez-Ragnarsson C; Iglesias P; Sastre J
    Endocrine; 2022 Jun; 77(1):121-133. PubMed ID: 35585463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 7. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
    Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
    Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
    Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
    Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
    Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
    Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer.
    Matrone A; Ceccarini G; Beghini M; Ferrari F; Gambale C; D'Aqui M; Piaggi P; Torregrossa L; Molinaro E; Basolo F; Vitti P; Santini F; Elisei R
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31875910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
    Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
    Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
    Kiernan CM; Parikh AA; Parks LL; Solórzano CC
    J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.